Dongping Wei
Impact in
- Biotechnology top 5%
- Cancer Research and Treatments
- Oncology top 5%
- Cancer-related Molecular Pathways
- PARP inhibition in cancer therapy
Papers in
- Oncology 11
- Cancer-related Molecular Pathways 6
-
- Ubiquitin and proteasome pathways 10
- Protein Degradation and Inhibitors 4
- RNA modifications and cancer 4
- Co-authors
- Lili Zhao (6 shared papers)Yi Sun (9 shared papers)Meredith Ann Morgan (7 shared papers)Theodore Steven Lawrence (5 shared papers)Leslie A. Parsels (4 shared papers)David M. Karnak (3 shared papers)Jonathan Maybaum (3 shared papers)Mary A. Davis (3 shared papers)
- Journals
- Clinical Cancer Research (3 papers)Molecular & Cellular Proteomics (2 papers)Experimental Hematology and Oncology (2 papers)Oncogene (2 papers)Translational Oncology (2 papers)
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Dongping Wei
30 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 78
- Biotechnology 164
- Oncology 444
- Cancer Research 175
- Molecular Biology 832
- Cell Biology 108
Countries citing papers authored by Dongping Wei
This map shows the geographic impact of Dongping Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dongping Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dongping Wei more than expected).
Fields of papers citing papers by Dongping Wei
This network shows the impact of papers produced by Dongping Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dongping Wei. The network helps show where Dongping Wei may publish in the future.
Co-authors
The 25 scholars most cited alongside Dongping Wei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 32 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 142 | |
| 2 | 2014 | 134 | |
| 3 | 2013 | 95 | |
| 4 | 2018 | 86 | |
| 5 | 2013 | 85 | |
| 6 | 2014 | 75 | |
| 7 | 2007 | 59 | |
| 8 | 2007 | 55 | |
| 9 | 2014 | 50 | |
| 10 | 2022 | 47 | |
| 11 | 2014 | 46 | |
| 12 | 2015 | 44 | |
| 13 | 2015 | 43 | |
| 14 | 2009 | 41 | |
| 15 | 2019 | 40 | |
| 16 | 2019 | 36 | |
| 17 | 2021 | 31 | |
| 18 | 2015 | 31 | |
| 19 | 2011 | 29 | |
| 20 | 2020 | 22 |
About Dongping Wei
Dongping Wei is a scholar working on Oncology, Molecular Biology, Biotechnology, Cancer Research and Epidemiology, having authored 32 papers that have together received 1.3k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (10 papers), Cancer-related Molecular Pathways (6 papers), Nanoplatforms for cancer theranostics (5 papers), Cancer Research and Treatments (5 papers), Protein Degradation and Inhibitors (4 papers), Autophagy in Disease and Therapy (4 papers), RNA modifications and cancer (4 papers) and Cancer, Hypoxia, and Metabolism (4 papers). The work is most often cited by research in Biotechnology (164 citations), Oncology (444 citations), Cancer Research (175 citations), Molecular Biology (832 citations) and Cell Biology (108 citations). Dongping Wei has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Lili Zhao, Yi Sun, Meredith Ann Morgan, Theodore Steven Lawrence, Leslie A. Parsels, David M. Karnak, Jonathan Maybaum, Mary A. Davis, Lijun Jia and Yongchao Zhao. Their work appears in journals such as Clinical Cancer Research, Molecular & Cellular Proteomics, Experimental Hematology and Oncology, Oncogene and Translational Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.